T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report

Figure 1 Leukemic blasts in bone marrow aspiration and biopsy at the initial diagnosis of mixed-phenotype acute leukemia. A: Bone marrow aspiration smear (Wright-Giemsa stain, 400×); B: Bone marrow biopsy section (hematoxylin and eosin stain, 100×); C: Bone marrow biopsy section with immunohistochemical staining of CD34 (100×); D: Bone marrow biopsy section with immunohistochemical staining of CD3 (100×); E: Bone marrow biopsy section with immunohistochemical staining of myeloperoxidase (100×) with similar distribution.

Figure 2 Summary of the absolute neutrophil counts from initiating vincristine, prednisolone, daunorubicin, and l-asparaginase therapy to the end of the second venetoclax/decitabine cycle. VDPL: Vincristine, prednisolone, daunorubicin, and l-asparaginase.